Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LionHeart21: NPC-21 in high‑risk kidney transplant recipients for CMV prevention
jRCT2041200019Phase 2Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in cytomegalovirus disease (CMV) and cytomegalovirus infection comparing NPC-21 with Placebo (2 arms). Primary endpoint: Adjudicated CMV disease or CMV viremia through 16 weeks post-transplant. Started Jun 2020; status: completed.
02
Drugs
fiztasovimab
03
Conditions
cytomegalovirus disease (CMV)cytomegalovirus infection
Beyond the preview
Go deeper on jRCT2041200019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200019.